Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors: Update from the ARROW trial.
暂无分享,去创建一个
G. Curigliano | L. Paz-Ares | M. Schuler | Jian-hua Chang | G. Kalemkerian | G. Lopes | S. Siena | P. Garrido | D. Bowles | J. Vuky | V. Subbiah | E. Nadal | P. Cassier | Yun Fan | Hui Zhang | M. Seetharam | Jennifer M. Green | A. Zalutskaya | G. Alonso | Chao-Fu Ye | Jennifer Green